I think it once could have achieved a very good valuation. In 2010 JNJ (via one of its units, Ethicon as I remember) paid nearly $1B for a French HPV system (Glouster). So, there was some precident for a good price. Notwithstanding the inflation in healthcare, more drug resistance, more HAIs, other applications, etc., I'm doubtful that MZEI could gain a bid in that area today. The competing technologies aren't setting the world on fire and MZEI is doing nothing on the commercial front (the length of time to gaining sales only generates more doubts about the tech). Even if we get FDA approval, the company is resource strapped so it begs the question Vince and others have asked over the years, 'why would anyone invest in AS units with a firm perceptively lacking staying power'? So, even if they dot all the i's, can the company overcome it's lack of scale? If the preferreds were done away with and a suitor made an offer, it would push the managment into defining the MZEI value proposition, something they have been unwilling or unable to do so far.
Market Data 
Markets 
AI
